- Home
- CHW vs ESPR Comparison
CHW vs ESPR Comparison
Compare CHW & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHW
- ESPR
- Stock Information
- Founded
- CHW 2007
- ESPR 2008
- Country
- CHW United States
- ESPR United States
- Employees
- CHW N/A
- ESPR N/A
- Industry
- CHW Investment Managers
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- CHW Finance
- ESPR Health Care
- Exchange
- CHW Nasdaq
- ESPR Nasdaq
- Market Cap
- CHW 439.4M
- ESPR 410.2M
- IPO Year
- CHW N/A
- ESPR 2013
- Fundamental
- Price
- CHW $6.97
- ESPR $1.82
- Analyst Decision
- CHW
- ESPR Buy
- Analyst Count
- CHW 0
- ESPR 6
- Target Price
- CHW N/A
- ESPR $7.25
- AVG Volume (30 Days)
- CHW 195.2K
- ESPR 3.4M
- Earning Date
- CHW 01-01-0001
- ESPR 03-04-2025
- Dividend Yield
- CHW 9.27%
- ESPR N/A
- EPS Growth
- CHW N/A
- ESPR N/A
- EPS
- CHW N/A
- ESPR N/A
- Revenue
- CHW N/A
- ESPR $295,451,000.00
- Revenue This Year
- CHW N/A
- ESPR $186.86
- Revenue Next Year
- CHW N/A
- ESPR $9.41
- P/E Ratio
- CHW N/A
- ESPR N/A
- Revenue Growth
- CHW N/A
- ESPR 187.12
- 52 Week Low
- CHW $5.07
- ESPR $1.58
- 52 Week High
- CHW $6.54
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- CHW 52.05
- ESPR 38.40
- Support Level
- CHW $6.92
- ESPR $1.82
- Resistance Level
- CHW $7.03
- ESPR $1.91
- Average True Range (ATR)
- CHW 0.07
- ESPR 0.09
- MACD
- CHW 0.01
- ESPR 0.02
- Stochastic Oscillator
- CHW 66.73
- ESPR 47.83
About CHW Calamos Global Dynamic Income Fund
Calamos Global Dynamic Income Fund operates as a closed-end management investment company. The company's investment objective is to generate a high level of current income with the objective of capital appreciation. It dynamically allocates its investment among equities, convertible bonds, fixed-income securities and alternative investments.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.